Monitoring efficiency of humoral rejection episode therapy in liver transplantation: any role for complement binding Luminex Single Antigen assays?

2016 ◽  
Vol 35 ◽  
pp. 23-28 ◽  
Author(s):  
Stéphanie Ducreux ◽  
Olivier Guillaud ◽  
Alexie Bosch ◽  
Olivier Thaunat ◽  
Emmanuel Morelon ◽  
...  
Children ◽  
2021 ◽  
Vol 8 (7) ◽  
pp. 600
Author(s):  
Catherine de Magnée ◽  
Louise Brunée ◽  
Roberto Tambucci ◽  
Aurore Pire ◽  
Isabelle Scheers ◽  
...  

Background: ABO-incompatible (ABOi) living donor liver transplantation (LDLT) has been proposed to compensate for donor shortage. To date, few studies have reported detailed ABOi LDLT results in large series of pediatric patients. C4d complement deposition in graft capillaries has been reported to be associated with antibody-mediated rejection in solid organ transplantation. Methods: A retrospective case–control study was conducted, comparing clinical outcomes of each of 34 consecutive pediatric ABOi LDLT recipients with those of 2 non-ABOi pairs (n = 68), matched according to pre-transplant diagnostic criteria, age, and date of transplantation. In addition, we studied the C4d immunostaining pattern in 22 ABOi and in 36 non-ABOi recipients whose liver biopsy was performed within the first 4 post-transplant weeks for suspected acute rejection. Results: The incidence of biliary complications was higher in ABOi recipients (p < 0.05), as were the incidence of acute humoral rejection (p < 0.01) and the incidence of retransplantation (p < 0.05). All children who required retransplantation were older than 1 year at the time of ABOi LDLT. Positive C4d immunostaining was observed in 13/22 (59%) ABOi recipients versus 3/36 (8.3%) non-ABOi recipients (p < 0.0001). Conclusions: ABOi LDLT is a feasible option for pediatric end-stage liver disease but carries increased risks for the recipient, especially for children older than 1 year, even with a specific preparation protocol. C4d immunostaining may be a hallmark of acute humoral rejection in ABOi liver transplantation.


2004 ◽  
Vol 10 (1) ◽  
pp. 16-27 ◽  
Author(s):  
Hironori Haga ◽  
Hiroto Egawa ◽  
Tomoyuki Shirase ◽  
Aya Miyagawa ◽  
Takaki Sakurai ◽  
...  

2011 ◽  
Vol 91 (5) ◽  
pp. e29-e30 ◽  
Author(s):  
Kun-Ming Chan ◽  
Ching-Sung Lee ◽  
Ting-Jung Wu ◽  
Chen-Fang Lee ◽  
Tse-Ching Chen ◽  
...  

2005 ◽  
Vol 18 (11) ◽  
pp. 1298-1301 ◽  
Author(s):  
Anthony Rostron ◽  
Vaughan Carter ◽  
Mbithe Mutunga ◽  
Gary Cavanagh ◽  
Criostoir O'Suilleabhain ◽  
...  

2010 ◽  
Vol 23 (3) ◽  
pp. 338-340 ◽  
Author(s):  
Tomohide Hori ◽  
Hiroto Egawa ◽  
Yasutsugu Takada ◽  
Fumitaka Oike ◽  
Yasuhiro Ogura ◽  
...  

2009 ◽  
Vol 2009 ◽  
pp. 1-4 ◽  
Author(s):  
Kathleen Connor ◽  
Raymond A. Rubin ◽  
Roshan Shrestha ◽  
Mark Johnson ◽  
Marty Sellers ◽  
...  

The following is a case report of a primiparous woman who developed fulminant liver failure in the setting of HELLP syndrome complicated by hepatic rupture. It is unique in that a timely ABO compatible liver donor was unavailable, necessitating the transplantation of an ABO incompatible organ. Despite aggressive therapy,severe reperfusion injuryand humoral rejection dictated retransplantation with an ABO compatible organon postoperative day 15, resulting in rapid clinical recovery.


2006 ◽  
Vol 12 (3) ◽  
pp. 457-464 ◽  
Author(s):  
Hironori Haga ◽  
Hiroto Egawa ◽  
Yasuhiro Fujimoto ◽  
Mikiko Ueda ◽  
Aya Miyagawa-Hayashino ◽  
...  

2021 ◽  
Vol 2 (1) ◽  
pp. 1-7
Author(s):  
Claudia Rita ◽  
Ignacio Iturrieta-Zuazo ◽  
Rubén Ballester-González ◽  
Nieves Alonso-Alarcón ◽  
Esther Moreno-Moreno ◽  
...  

Understanding the role of donor-specific antibodies (DSAs) in liver transplantation remains an investigative priority. Acute and chronic rejection associated with DSAs have been described. However, most transplant protocols did not consider the presence of DSAs at the moment of liver transplantation (LTx) or for the follow-up. A 65-year-old man received an ABO-compatible LTx for cirrhosis. Ten years after the LTx, he presented with a progressive elevation of liver enzymes and bilirubin. The single antigen Luminex bead assay showed the presence of DSAs against several DQ2, DQ7, and DQ8 alleles. The patient received several desensitization treatments regarding the persistence of DSAs. The anatomopathological study confirms chronic rejection. Although in this case the immunohistochemical deposits of C4d were negative, the data revealed morphological criteria of chronic graft injury and DSAs’ incompatibilities explained by structural analysis. These data support an antibody-mediated rejection (AMR). It could be reasonable to establish a protocol for human leukocyte antigen (HLA) typing of every LTx donor and recipient as well as a periodic follow-up to assess the presence of DSAs. This will make it possible to carry out studies of donor–recipient incompatibility and to confirm the existence of probable cases of AMR.


Sign in / Sign up

Export Citation Format

Share Document